Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PErsonalized TREatment of high-risk MAmmary Cancer (PETREMAC)
2015-002816-34Phase 2Active
- Sponsor
- Helse Bergen
- Start
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of palbociclib in breast cancer, sponsored by Helse Bergen. Primary endpoint: Predictive and prognostic value of baseline driver mutation panel. Started Oct 2015; status: active.
02
Drugs
palbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2015-002816-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002816-34.